CERAVOLO, ROBERTO
 Distribuzione geografica
Continente #
NA - Nord America 18.330
EU - Europa 7.882
AS - Asia 5.486
SA - Sud America 643
AF - Africa 346
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 11
Totale 32.717
Nazione #
US - Stati Uniti d'America 17.906
IT - Italia 2.977
CN - Cina 2.340
SG - Singapore 1.698
SE - Svezia 1.367
BG - Bulgaria 768
DE - Germania 692
HK - Hong Kong 596
BR - Brasile 570
CA - Canada 395
GB - Regno Unito 382
RU - Federazione Russa 373
AT - Austria 341
TR - Turchia 325
VN - Vietnam 294
UA - Ucraina 265
FI - Finlandia 261
CI - Costa d'Avorio 184
CH - Svizzera 118
FR - Francia 105
IN - India 93
SN - Senegal 67
NL - Olanda 48
NG - Nigeria 46
PL - Polonia 35
BE - Belgio 32
AR - Argentina 25
IE - Irlanda 21
ES - Italia 20
CZ - Repubblica Ceca 19
AU - Australia 16
LT - Lituania 15
KR - Corea 13
MA - Marocco 13
IQ - Iraq 12
JP - Giappone 12
MX - Messico 12
BJ - Benin 11
EU - Europa 11
UZ - Uzbekistan 11
CO - Colombia 10
PK - Pakistan 10
EC - Ecuador 9
ZA - Sudafrica 9
BD - Bangladesh 8
IL - Israele 8
IR - Iran 8
PY - Paraguay 7
AZ - Azerbaigian 6
EG - Egitto 6
GR - Grecia 6
PE - Perù 6
CL - Cile 5
DO - Repubblica Dominicana 5
EE - Estonia 5
KE - Kenya 5
LV - Lettonia 5
PT - Portogallo 5
TW - Taiwan 5
VE - Venezuela 5
JO - Giordania 4
KG - Kirghizistan 4
AE - Emirati Arabi Uniti 3
AM - Armenia 3
BA - Bosnia-Erzegovina 3
BN - Brunei Darussalam 3
BO - Bolivia 3
CY - Cipro 3
LK - Sri Lanka 3
LU - Lussemburgo 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PA - Panama 3
PH - Filippine 3
SA - Arabia Saudita 3
UY - Uruguay 3
AL - Albania 2
AO - Angola 2
GE - Georgia 2
GT - Guatemala 2
HN - Honduras 2
HR - Croazia 2
HU - Ungheria 2
ID - Indonesia 2
JM - Giamaica 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
NI - Nicaragua 2
PS - Palestinian Territory 2
TN - Tunisia 2
BH - Bahrain 1
CR - Costa Rica 1
DK - Danimarca 1
DZ - Algeria 1
IM - Isola di Man 1
IS - Islanda 1
KH - Cambogia 1
KW - Kuwait 1
MK - Macedonia 1
MY - Malesia 1
Totale 32.710
Città #
Woodbridge 1.951
Ashburn 1.891
Fairfield 1.863
Ann Arbor 1.348
Houston 1.326
Chandler 1.263
Santa Clara 1.011
Shanghai 912
Milan 853
Singapore 821
Seattle 801
Sofia 768
Wilmington 693
Hong Kong 586
Cambridge 583
Serra 525
New York 505
Boardman 394
Jacksonville 394
Princeton 382
Beijing 375
Ottawa 365
Vienna 308
Lawrence 301
Medford 279
Izmir 192
Nanjing 190
Pisa 186
Abidjan 184
Des Moines 179
Frankfurt am Main 174
Florence 168
Dearborn 154
Istanbul 119
Bern 113
Dong Ket 112
San Diego 100
London 94
Rome 93
Nanchang 79
Bremen 75
Los Angeles 71
Dakar 67
Jüchen 67
Redwood City 65
Norwalk 59
Lancaster 58
Ogden 57
Chicago 53
Shenyang 53
Kunming 52
Guangzhou 47
Lucca 47
Lagos 46
Fuzhou 44
Hebei 44
São Paulo 41
Düsseldorf 39
Helsinki 36
Changsha 35
Pune 35
Warsaw 33
Brussels 32
Munich 32
Nuremberg 32
Quanzhou 31
Tianjin 29
Vicopisano 29
Council Bluffs 28
Trieste 28
Hefei 26
Jiaxing 25
Boulder 22
Falls Church 22
The Dalles 22
Hangzhou 19
Washington 19
Lauterbourg 18
San Francisco 17
Dallas 16
Nürnberg 16
Brno 15
Curitiba 15
Jinan 15
Auburn Hills 14
Livorno 14
Toronto 14
La Spezia 13
Phoenix 13
Rio de Janeiro 13
Belo Horizonte 12
Hyderabad 12
Cotonou 11
Dublin 11
Kent 11
Naples 11
Genoa 10
Haikou 10
Lappeenranta 10
Portsmouth 10
Totale 24.456
Nome #
Molecular imaging to track Parkinson's disease and atypical parkinsonisms: new imaging frontiers 332
Cataract surgery under topical anesthesia in a patient with Parkinson disease and deep brain stimulation: a report of feasibility. 265
Randomized trial on the effects of a combined physical/cognitive training in aged MCI subjects: the Train the Brain study 259
Clinical Correlates of Cerebral Amyloid Deposition in Parkinson's Disease Dementia: Evidence from a PET Study 217
Vascular Function Is Improved After an Environmental Enrichment Program: The Train the Brain-Mind the Vessel Study 192
Disfunzioni sessuali nel morbo di Parkinson: review 188
The role of vascular factors in late-onset sporadic Alzheimer's disease. Genetic and molecular aspects 183
α-Synuclein Heterocomplexes with β-Amyloid Are Increased in Red Blood Cells of Parkinson's Disease Patients and Correlate with Disease Severity 177
A case of pelvic floor myoclonic jerk syndrome. 176
Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study 169
CSF phosporylated TAU protein levels correlate with cerebral glucose metabolism assessed with PET in Alzheimer's disease 166
Leadless cardiac pacemaker implant in a patient with two deep brain stimulators: a peaceful cohabitation beyond prejudices 166
Decreased platelet cytochrome c oxidase activity is accompanied by increased blood lactate concentration during exercise in patients with Alzheimer disease 165
Serotonin and neurodegeneration: a preliminary study of platelet serotonin transporter (SERT) in patients with Huntington's disease 165
Mild affective symptoms in de novo Parkinson's disease patients: relationship with dopaminergic dysfunction 164
Comparison of 3T and 7T susceptibility-weighted angiography of the substantia nigra in diagnosing Parkinson disease 164
Acute and chronic effects of clozapine in essential tremor 163
Serotoninergic polymorphisms (5-HTTLPR and 5-HT2A): association studies with psychosis in Alzheimer disease. 162
Lack of association between mtDNA haplogroups and Alzheimer's disease in Tuscany 162
Mitochondrial DNA single deletion in a patient with postural tremor. 161
A pilot psychometric study of aberrant salience state in patients with Parkinson's disease and its association with dopamine replacement therapy. 161
The precuneus-a witness for excessive aβ gathering in alzheimer's disease pathology 161
The hOGG1 Ser326Cys polymorphism and Huntington's disease 159
Neuropathy and levodopa in Parkinson's disease: evidence from a multicenter study. 159
Mesolimbic dopaminergic dysfunction in Parkinson's disease depression: evidence from a 123I-FP-CIT SPECT investigation. 157
Evolution of clinical features in possible DLB depending on FP-CIT SPECT result 154
Caudate dopaminergic denervation and visual hallucinations: Evidence from a 123I-FP-CIT SPECT study 152
A single center study: Aβ42/p-Tau181 CSF ratio to discriminate AD from FTD in clinical setting 150
Social Cognition and Oxytocin in Huntington’s Disease: New Insights 150
Brain-Derived Neurotrophic Factor (BDNF) and Serotonin Transporter (SERT) in Platelets of Patients with Mild Huntington’s Disease: Relationships with Social Cognition Symptoms 150
Spectrum of addictions in Parkinson's disease: from dopamine dysregulation syndrome to impulse control disorders 149
Aerobic rehabilitation program for improving muscle function in Parkinson's disease 148
Visual hallucinations in Parkinson's disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes 147
SSRIs do not worsen Parkinson's disease: Evidence from an open-label, prospective study 146
Efficacy of a combined therapeutic approach in the management of Pisa Syndrome 144
Diabetes is associated with postural and cognitive domains in Parkinson's disease. Results from a single-center study. 143
Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: A 2-year follow-up multicenter study 142
Antipsychotic drugs in Huntington's disease 142
[123I]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism 141
Psychosis associated to Parkinson's disease in the early stages: Relevance of cognitive decline and depression 141
Correction to: The Italian Dystonia Registry: rationale, design and preliminary findings (Neurological Sciences, (2017), 38, 5, (819-825), 10.1007/s10072-017-2839-3) 141
The relationship between motor symptom lateralization and cognitive performance in newly diagnosed drug-na?ve patients with Parkinson's disease. 140
Imaging in Glucocerebrosidase-Associated Parkinsonism: Current Status and Implications for Pathophysiology. 139
Event-based prospective memory in newly diagnosed, drug-naive Parkinson's disease patients 138
Gait dynamics in Pisa syndrome and Camptocormia: the role of stride length and hip kinematics 137
Decision making in de novo Parkinson's disease 136
Iowa Gambling Task in de novo Parkinson's disease: a comparison between good and poor performers 136
Seven tesla MRI of the substantia nigra in patients with rapid eye movement sleep behavior disorder 136
Non-motor symptoms in atypical and secondary parkinsonism: The PRIAMO study 136
Depressive symptoms in Parkinson's disease 135
Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: a 2-year follow-up multicenter study. 135
The association between motor subtypes and alexithymia in de novo Parkinson's disease. 133
No evidence for allelic association of serotonin 2A receptor and transporter gene polymorphisms with depression in Alzheimer disease 133
Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders 132
Metabolic changes induced by theta burst stimulation of the cerebellum in dyskinetic Parkinson's disease patients 132
Antioxidants in the Diet and Cognitive Function: Which Role for the Mediterranean Life-style? 131
Association of cerebrospinal fluid α-synuclein with total and phospho-tau181 protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers 131
The mtDNA A8344G "MERRF" mutation is not a common cause of sporadic Parkinson disease in Italian population 129
Myopathic involvement in two cases of Hallervorden-Spatz disease 128
Current treatment and future prospects of dopa-induced dyskinesias. 128
Association between amantadine and the onset of dementia in Parkinson's disease 127
A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease 127
Assessment of midbrain atrophy in patients with progressive supranuclear palsy with routine magnetic resonance imaging 126
A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs. 126
Mild cognitive impairment in De Novo Parkinson's disease according to movement disorder guidelines. 126
Serotonergic antidepressant drugs and L-dopa-induced dyskinesias in Parkinson's disease. 126
Morphometric and functional MRI changes in essential tremor with and without resting tremore. 126
Effects of combined training on neuropsychiatric symptoms and quality of life in patients with cognitive decline 126
Clinical variables associated with treatment changes in Parkinson's disease: results from the longitudinal phase of the REASON study. 125
null 125
Effects of combined training on neuropsychiatric symptoms and quality of life in patients with cognitive decline 125
Psychiatric comorbidity in a population of Parkinson's disease patients 124
The Italian Dystonia Registry: rationale, design and preliminary findings 124
Paroxetine in Parkinson's disease: effects on motor and depressive symptoms. 124
How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire 123
Nonmotor symptoms in Parkinson’s disease: the dark side of the moon 123
Apomorphine hydrochloride for the treatment of Parkinson's disease. 123
The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease 123
Environmental factors and Parkinson's disease: a case-control study in the Tuscany region of Italy 122
Adherence to anti-Parkinson drug therapy in the "REASON" sample of Italian patients with Parkinson's disease: the linguistic validation of the Italian version of the "Morisky Medical Adherence Scale-8 items". 122
Unilateral periodic limb movements: is this a pointer for atypical presentation of corticobasal degeneration syndrome?--A case report 121
Low frequency stimulation of the nucleus tegmenti pedunculopontini increases cortical metabolism in Parkinsonian patients 121
Expanding the clinical phenotype of DYT5 mutations: is multiple system atrophy a possible one? 121
Reliability of administrative data for the identification of Parkinson's disease cohorts. 121
Oxidative stress assessment in Alzheimer's disease: a clinic setting study 121
Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases 121
Predictive value of nigrostriatal dysfunction in isolated tremor: A clinical and SPECT study 119
Role of pramipexole in the management of Parkinsons disease 119
Correlation between vestibular abnormalities and MRI findings in cerebellar ataxia 118
Alexithymia is associated with depression in de novo Parkinson's disease 118
Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia 118
Clinical impact of angiotensin I converting enzyme polymorphisms in subjects with resistant hypertension 118
Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naive patients with Parkinson's disease. 118
Advances in the pharmacotherapeutic management of dementia with Lewy bodies 118
Postural Abnormalities in Parkinson's Disease: An Epidemiological and Clinical Multicenter Study 117
Evaluating the SERCA2 and VEGF mRNAs as potential molecular biomarkers of the onset and progression in huntington's disease 117
Paraneoplastic choreic syndrome during non-Hodgkin's lymphoma 116
α-Synuclein Heteromers in Red Blood Cells of Alzheimer's Disease and Lewy Body Dementia Patients 116
Sindrome da encefalopatia posteriore reversibile (PRES) in una paziente psoriasica in trattamento con ciclosporina 115
Mitochondrial DNA rearrangements in young onset parkinsonism: two case reports 115
Totale 14.339
Categoria #
all - tutte 100.973
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 100.973


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020445 0 0 0 0 0 0 0 0 0 0 351 94
2020/20212.335 175 164 151 96 197 146 287 186 240 174 136 383
2021/20223.333 44 125 71 254 657 440 93 177 199 99 226 948
2022/20234.304 565 538 342 357 464 542 37 311 764 23 281 80
2023/20243.857 454 412 407 318 563 764 140 134 30 69 179 387
2024/20257.552 115 417 178 571 792 955 1.076 513 1.161 1.565 209 0
Totale 33.355